Effect of diabetes on serum potassium concentrations in acute coronary syndromes

K Foo, N Sekhri, A Deaner, C Knight, A Suliman, K Randjadayalan, A D Timmis

Objectives: To compare serum potassium concentrations in diabetic and non-diabetic patients in the early phase of acute coronary syndromes.

Background: Acute phase hypokalaemia occurs in response to adrenergic activation, which stimulates membrane bound sodium-potassium-ATPase and drives potassium into the cells. It is not known whether the hypokalaemia is attenuated in patients with diabetes because of the high prevalence of sympathetic nerve dysfunction.

Methods: Prospective cohort study of 2428 patients presenting with acute coronary syndromes. Patients were stratified by duration of chest pain, diabetic status, and pretreatment with β blockers.

Results: The mean (SD) serum potassium concentration was significantly higher in diabetic than in non-diabetic patients (4.3 (0.5) v 4.1 (0.5) mmol/l, p < 0.0001). Multivariate analysis identified diabetes as an independent predictor of a serum potassium concentration in the upper half of the distribution (odds ratio 1.66, 95% confidence interval 1.38 to 2.00). In patients presenting within 6 hours of symptom onset, there was a progressive increase in plasma potassium concentrations from 4.08 (0.46) mmol/l in patients presenting within 2 hours, to 4.20 (0.47) mmol/l in patients presenting between 2–4 hours, to 4.24 (0.52) mmol/l in patients presenting between 4–6 hours (p = 0.0007). This pattern of increasing serum potassium concentration with duration of chest pain was attenuated in patients with diabetes, particularly those with unstable angina. Similar attenuation occurred in patients pretreated with β blockers.

Conclusion: In acute coronary syndromes, patients with diabetes have significantly higher serum potassium concentrations and do not exhibit the early dip seen in non-diabetics. This may reflect sympathetic nerve dysfunction that commonly complicates diabetes.
dedicated cardiologist or research nurse and stored on a purpose built electronic database. The duration of pain before presentation at hospital was recorded, as were routine biochemistry parameters for blood samples obtained in the emergency department and all admission drugs, including β blockers. Diabetes was recorded in patients taking insulin or oral hypoglycaemic drugs or with dietary restriction. Hypertension was recorded in patients taking antihypertensive drugs. Ventricular arrhythmias (tachycardia, fibrillation) that occurred in the emergency department or during monitoring in the coronary care unit were also recorded.

### Statistical analysis
Comparison of discrete variables was by χ² analysis and continuous variables by t testing. To evaluate their independent influence, variables significantly different (p < 0.05) in univariate analysis or believed to be of clinical or biological relevance were entered into a regression analysis using a multinomial logistical model. Improvements in model fit were based on comparison of likelihood ratios. Odds ratios are quoted together with 95% confidence intervals; means are accompanied by SD. Analysis of variance was used to test differences between potassium concentrations by duration of chest pain. Simple regression analysis was used to test correlations between continuous variables.

### RESULTS
Of the 2428 patients with acute coronary syndromes, 987 (41%) had a discharge diagnosis of acute myocardial infarction. In patients with acute myocardial infarction, diabetes was recorded less frequently (23.2% v 30.3%, p = 0.0001) but markers of adrenergic stress including heart rate (81 (22) v 78 (19) beats/minute, p = 0.0005), admission glucose concentrations (9.6 (5.2) v 8.3 (4.5) mmol/l, p < 0.0001), and peak creatine kinase concentrations (1297 (1432) v 139 (125) mmol/l, p < 0.0001) were all significantly higher than in patients with unstable angina.

#### Admission serum potassium concentration: univariate predictors
Comparison between patients in the upper and lower halves of the potassium distribution (median 4.2 mmol/l) confirmed that those with a potassium concentration > 4.2 mmol/l were more commonly diabetic and tended to be older with a higher serum creatinine concentration. Pretreatment with angiotensin converting enzyme (ACE) inhibitors and diuretics was, respectively, more and less common when the admission potassium concentration was > 4.1 mmol/l.

#### Admission serum potassium concentration: multivariate predictors
In patients with diabetes, the odds of presenting with a serum potassium concentration in the upper half of the distribution (> 4.2 mmol/l) were 66% higher than in patients without diabetes. The odds increased by 1.6% per year with increasing age and by 0.6% per µmmol/l with increasing serum creatinine concentration. The odds were increased 33% by pretreatment with angiotensin converting enzyme (ACE) inhibitors and diuretics.

### Table 1 Comparison between patients in the upper and lower halves of the distribution of plasma potassium concentration

<table>
<thead>
<tr>
<th></th>
<th>K+ &lt;4.2 mmol/l (n=1473)</th>
<th>K+ &gt;4.2 mmol/l (n=955)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62 (13)</td>
<td>65 (13)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Plasma creatinine [µmol/l]</td>
<td>105 (44)</td>
<td>120 (69)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male sex</td>
<td>1003 (68.1%)</td>
<td>692 (72.5%)</td>
<td>0.02</td>
</tr>
<tr>
<td>Diabetes</td>
<td>337 (22.9%)</td>
<td>328 (34.3%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>731 (49.6%)</td>
<td>471 (49.3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking</td>
<td>497 (34.1%)</td>
<td>299 (31.6%)</td>
<td>NS</td>
</tr>
<tr>
<td>Admission drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>789 (53.8%)</td>
<td>531 (55.7%)</td>
<td>NS</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>305 (20.8%)</td>
<td>245 (25.7%)</td>
<td>0.005</td>
</tr>
<tr>
<td>Diuretic</td>
<td>372 (25.4%)</td>
<td>177 (18.7%)</td>
<td>0.0001</td>
</tr>
<tr>
<td>β Blocker</td>
<td>365 (24.9%)</td>
<td>251 (26.3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Statin</td>
<td>377 (25.8%)</td>
<td>265 (27.8%)</td>
<td>NS</td>
</tr>
<tr>
<td>Admission haemodynamics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>79 (20)</td>
<td>79 (20)</td>
<td>NS</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>145 (29)</td>
<td>144 (29)</td>
<td>NS</td>
</tr>
<tr>
<td>Complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVF</td>
<td>176 (12.0%)</td>
<td>163 (17.2%)</td>
<td>0.0004</td>
</tr>
<tr>
<td>Ventricular fibrillation</td>
<td>21 (1.4%)</td>
<td>23 (2.4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Enzyme release and discharge diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak CK [mmol/l]</td>
<td>610 (1034)</td>
<td>612 (1148)</td>
<td>NS</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>595 (40.4%)</td>
<td>392 (41.0%)</td>
<td>NS</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>878 (59.6%)</td>
<td>563 (59.0%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data are numbers (percentages) or mean (SD). ACE, angiotensin converting enzyme. LVF, left ventricular failure.

### Table 2 Multivariate predictors of plasma potassium concentration in upper half of the distribution (>4.2 mmol/l)

<table>
<thead>
<tr>
<th></th>
<th>Odds ratio</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>1.016</td>
<td>1.009 to 1.023</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.66</td>
<td>1.38 to 2.00</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Serum creatinine [µmol/l]</td>
<td>1.006</td>
<td>1.004 to 1.008</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>1.33</td>
<td>1.07 to 1.64</td>
<td>0.009</td>
</tr>
<tr>
<td>Diuretic</td>
<td>0.49</td>
<td>0.39 to 0.61</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data are for 2399 patients for whom complete data were available. CI, confidence interval.
with ACE inhibitors but were reduced 49% by pretreatment with diuretics (table 2).

Serum potassium concentration and duration of chest pain
The time from onset of chest pain to arrival at the emergency department was recorded in 1749 patients, 71% of whom arrived in the first 6 hours. Subgrouping the patients by duration of chest pain showed a progressive and highly significant increase in serum potassium concentrations rising from a low point of 4.08 (0.46) mmol/l in those arriving ≤ 2 hours of the onset of symptoms, through 4.20 (0.47) mmol/l after 2–4 hours, to a peak of 4.24 (0.52) mmol/l in those arriving 4–6 hours after the onset of symptoms (p < 0.0001). This pattern of increasing admission potassium concentration with duration of chest pain was severely attenuated in patients with diabetes, in whom potassium concentrations at every time increment were substantially higher than in patients without diabetes (fig 1). Subgroup analysis showed that attenuation was confined to diabetic patients with unstable angina and was not seen in acute myocardial infarction, although for both groups diabetes was associated with higher potassium concentrations (table 3).

Serum potassium concentration, sympathetic blockade, and markers of stress
Among patients pretreated and not pretreated with β blockers, serum potassium concentrations were similar (4.2 (0.4) v 4.2 (0.5) mmol/l). However, pretreatment with β blockers attenuated the pattern of increasing serum potassium concentration with duration of chest pain (fig 1). Again, attenuation was seen most clearly for patients with unstable angina (table 3). There were weak but significant negative correlations between serum potassium concentrations and markers of stress in non-diabetic, but not diabetic, patients who arrived ≤ 2 hours after the onset of chest pain: heart rate (r = −0.13, p = 0.003), blood sugar (r = −0.10, p = 0.04), peak creatine kinase (r = −0.14, p = 0.002).

Serum glucose concentration and duration of chest pain
In patients with diabetes, serum glucose concentrations were higher at every time increment than in patients without diabetes. Although there were significant differences according to symptom duration, the pattern of fluctuations was not clear (fig 2). Among patients without diabetes glucose concentrations remained stable, regardless of symptom duration.

Discussion
Acute coronary syndromes provide a useful clinical model of adrenergic stress as reflected in many of the typical presenting features such as diaphoresis and tachycardia. Hypokalemia has also been attributed to this mechanism and our finding of lower serum potassium concentrations in patients presenting very early after the onset of chest pain is well

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Plasma potassium concentrations (mmol/l) by duration of chest pain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≤2 hours</td>
</tr>
<tr>
<td>Unstable angina</td>
<td></td>
</tr>
<tr>
<td>Non-diabetic (n=653)</td>
<td>4.08 (0.42)</td>
</tr>
<tr>
<td>Diabetic (n=288)</td>
<td>4.24 (0.49)</td>
</tr>
<tr>
<td>No β blocker (n=635)</td>
<td>4.10 (0.43)</td>
</tr>
<tr>
<td>β Blocker (n=302)</td>
<td>4.18 (0.48)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td></td>
</tr>
<tr>
<td>Non-diabetic (n=629)</td>
<td>4.0 (0.46)</td>
</tr>
<tr>
<td>Diabetic (n=179)</td>
<td>4.17 (0.51)</td>
</tr>
<tr>
<td>No β blocker (n=693)</td>
<td>4.03 (0.49)</td>
</tr>
<tr>
<td>β Blocker (n=113)</td>
<td>4.08 (0.38)</td>
</tr>
</tbody>
</table>

Data are mean (SD).
recognised. Rapid recovery of serum potassium concentrations in the first six hours has also been documented by serial blood sampling in patients with acute myocardial infarction. 

This is clearly analogous to our own finding of progressively increasing potassium concentrations in subgroups presenting later after the onset of symptoms. The early recovery in serum potassium concentrations in patients presenting later after the onset of symptoms is most likely a response to sympathetic withdrawal allowing intracellular potassium to re-enter the circulation. Support for an adrenergic mechanism of increasing serum potassium concentration with later hospital presentation was provided by our novel observations in patients pretreated with β blockers. In this group the early dip in serum potassium concentrations and its later increase were attenuated, presumably because adrenergic stimulation of sodium-potassium-ATPase was blocked, reducing potassium flux across the cell membrane. Attenuation was seen most clearly in unstable angina and was less pronounced in acute myocardial infarction when the early dip in potassium and its later recovery were preserved, albeit with loss of significance. This may reflect the fact that adrenergic responses to coronary syndromes are related to the extent of myocardial injury and are greater, therefore, in acute myocardial infarction, with the potential to overwhelm any effects that pretreatment with β blockers might have in modifying potassium flux across cell membranes.

Our finding of increased serum potassium concentrations in diabetic patients with acute coronary syndromes has not previously been reported, although hyperkalaemia is known to be relatively common in diabetic clinics, reflecting the role of insulin in potassium homeostasis. Also unreported is the independent effect of diabetes in attenuating the early dip in serum potassium concentration and its later recovery, an effect largely confined to unstable angina and not seen in acute myocardial infarction. In these respects, patients with diabetes behaved remarkably like patients pretreated with β blockers, making sympathetic nerve dysfunction the most plausible explanation for the effects on potassium. Again it is possible to speculate that the heightened adrenergic response to acute myocardial infarction overwhelmed the effect of diabetes in modifying serum potassium concentrations.

Further support for adrenergic mechanisms driving early changes in serum potassium concentrations in non-diabetic patients is provided by the negative correlations between serum potassium in the first two hours and various markers of adrenergic stress, including heart rate, acute phase glycaemia, and enzymatic markers of injury. These correlations were seen only in non-diabetic patients. Those with the greatest increases in heart rate, glucose, or creatine kinase tended to have the greatest reductions in serum potassium concentrations that were presumably less amenable to modification by sympathetic nerve dysfunction or β blockade. Insulin resistance may also have had a role in preventing the early dip in serum potassium in diabetes by attenuating intracellular ionic flux early after the onset of symptoms, although the experimental findings of Brown and colleagues indicate that insulin does not contribute significantly to adrenergically driven changes in serum potassium. Certainly, our finding of stable blood glucose concentrations in non-diabetic patients during the first six hours after the onset of chest pain, when potassium concentrations were changing rapidly, suggests that adrenergic mechanisms were more important than insulin in driving potassium across the cell membrane.

Autonomic function was not measured in this study, and our mechanistic hypotheses about the effects of diabetes in modifying early changes in serum potassium concentrations can only be inferred from the effects of β blockers and correlations with indirect markers of adrenergic stress. Nevertheless, sympathetic nerve dysfunction is a common manifestation of autonomic neuropathy, which can be shown in up to 40% of randomly selected diabetic patients by using conventional reflex tests. A much larger proportion may have more subtle alterations of sympathetic pathways as determined by myocardial radionlabelled hydroxyephedrine uptake using positron emission tomography. The association of diabetic autonomic neuropathy with a poor prognosis and sudden death is well established; prolongation of the QT interval, exaggerated exertional ischaemia, and impairment of sympathetically mediated myocardial blood flow are possible mechanisms. However, our finding of an independent association between diabetes and increased serum potassium concentration early after the onset of symptoms in acute coronary syndromes is unlikely to be detrimental and may be beneficial if it helps protect against acute phase ventricular arrhythmias. Thus, while diabetes may be associated with severe coronary syndromes, there are no data associating it with an increased incidence of ventricular arrhythmias.

An important limitation of this study is the absence of serial potassium measurements. Thus, while it is clear from our data that serum potassium concentrations were increased in diabetic patients with acute coronary syndromes, the changes during the early hours after the onset of symptoms were deduced by grouping the patients by arrival time. Because numbers were large this deduction is almost certainly valid, and our findings are consistent with the work of previous investigators who have undertaken serial blood sampling in much smaller cohorts. Additional limitations are the absence of data on type I and type II diabetes or the cardioselectivity of β blockers, neither of which were entered on our database.

In conclusion, patients with diabetes presenting with acute coronary syndromes had significantly higher serum potassium concentrations and did not exhibit the early dip seen in non-diabetic patients. Although other factors affecting serum potassium—particularly renal dysfunction, ACE inhibition, and diuretic treatment—were more prevalent in the diabetic group, this did not account for our observations and diabetes was retained as an independent predictor of increased serum potassium concentration in multivariate analysis. Relative insulin deficiency almost certainly accounted for the increased serum potassium concentrations in diabetic patients, but the absence of an early potassium dip in this group was also seen in patients taking β blockers and is more plausibly attributed to sympathetic nerve dysfunction.
REFERENCES


Effect of diabetes on serum potassium concentrations in acute coronary syndromes

K Foo, N Sekhri, A Deaner, C Knight, A Suliman, K Ranjadayalan and A D Timmis

Heart 2003 89: 31-35
doi: 10.1136/heart.89.1.31

Updated information and services can be found at:
http://heart.bmj.com/content/89/1/31

These include:
References
This article cites 35 articles, 13 of which you can access for free at:
http://heart.bmj.com/content/89/1/31#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Drugs: cardiovascular system (8842)
- Metabolic disorders (1030)
- Diabetes (842)
- Acute coronary syndromes (2742)
- Epidemiology (3752)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/